FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891508312> ?p ?o ?g. }

• W2891508312 endingPage "20" @default.
• W2891508312 startingPage "16" @default.
• W2891508312 abstract "Abstract Purpose This study is a dosimetric and acute toxicity comparison of endometrial cancer patients treated with either Axxent (Xoft, Inc., San José, CA, USA) electronic and interstitial brachytherapy versus interstitial high dose rate brachytherapy (HDRBT). Materials and Methods Between 2015 and 2017, 94 patients with postoperative endometrial cancer were treated in our centre with the Axxent electronic brachytherapy (eBT) system. The V 150 and V 200 are evaluated prospectively for each plan. The mean age of patients was 65.9 years (age range 33–84 years), with different tumour staging. Of the 94 patients, 37 received exclusive adjuvant brachytherapy (25 Gy in five sessions); the remaining patients received external beam radiotherapy (EBRT) with a regimen of 23 sessions of 2 Gy each to the entire pelvis, followed by eBT (15 Gy in three sessions). Additionally, the absorbed doses received by the organs at risk (OAR), urinary bladder, rectum and sigmoid colon were compared with HDRBT plans, evaluating D 2cc , V 50% and V 35% . Median follow-up was done for each of the 94 patients to assess the toxicity of the treatment: vaginal mucosa toxicity, rectal and urinary toxicity; and results are presented for acute toxicity, toxicity at 1 month after the end of treatment and follow-up after 12 months for a portion of patients according to the Radiation Therapy Oncology Group (RTOG) toxicity criteria. Results The doses in OAR for eBT plans were lower than that for HDRBT plans, both Ir-192 and Co-60 plans, whose doses were similar. The dose in bladder with eBT was 63.8% of the prescribed dose for D 2cc versus 70.1% for HDRBT Ir-192, for V 50% was 7.2% versus 12.7% and for V 35% was 15.2% versus 28.2%. In rectum the D 2cc was 61.2% versus 68.4%, for V 50% was 7.9% versus 14.3% and for V 35% was 16.7% versus 32%. Results demonstrated lower doses to OAR in all eBT plans. Acute toxicity in eBT was very low in cases of mucositis, with only one case of toxicity greater than grade 1, rectal toxicity and urinary toxicity; results at 1 month are equally good, toxicity symptoms disappeared and no relapses have occurred to date. Conclusions The results of treatment with the Axxent eBT unit for 94 patients are very good, as no recurrence has been observed and the toxicity of the treatment is very low. The increase in V 150 and V 200 has not produced an increase in vaginal mucosa toxicity, and the doses in the OAR are lower than in the plans implemented for HDRBT with Ir-192 or Co-60. eBT is a good alternative to treat endometrial cancer in centres without conventional HDR availability. To date, there are limited published studies reporting on outcomes from patients treated with eBT." @default.
• W2891508312 created "2018-09-27" @default.
• W2891508312 creator A5004989711 @default.
• W2891508312 creator A5011016173 @default.
• W2891508312 creator A5019650067 @default.
• W2891508312 creator A5023853605 @default.
• W2891508312 creator A5030691093 @default.
• W2891508312 creator A5070958796 @default.
• W2891508312 creator A5091377711 @default.
• W2891508312 creator A5070052045 @default.
• W2891508312 date "2018-09-20" @default.
• W2891508312 modified "2023-10-01" @default.
• W2891508312 title "Postoperative endometrial cancer treatments with electronic brachytherapy source" @default.
• W2891508312 cites W1553514057 @default.
• W2891508312 cites W2000604535 @default.
• W2891508312 cites W2012185370 @default.
• W2891508312 cites W2014873975 @default.
• W2891508312 cites W2018617003 @default.
• W2891508312 cites W2027395519 @default.
• W2891508312 cites W2032418267 @default.
• W2891508312 cites W2043945205 @default.
• W2891508312 cites W2062484120 @default.
• W2891508312 cites W2064057265 @default.
• W2891508312 cites W2068017316 @default.
• W2891508312 cites W2089573650 @default.
• W2891508312 cites W2091046714 @default.
• W2891508312 cites W2094060354 @default.
• W2891508312 cites W2108845160 @default.
• W2891508312 cites W2114971051 @default.
• W2891508312 cites W2120755680 @default.
• W2891508312 cites W2123934092 @default.
• W2891508312 cites W2127686622 @default.
• W2891508312 cites W2143568441 @default.
• W2891508312 cites W2150770847 @default.
• W2891508312 cites W2173042796 @default.
• W2891508312 cites W2174257825 @default.
• W2891508312 cites W2232107218 @default.
• W2891508312 cites W2256710235 @default.
• W2891508312 cites W2298379157 @default.
• W2891508312 cites W2300494977 @default.
• W2891508312 doi "https://doi.org/10.1017/s1460396918000353" @default.
• W2891508312 hasPublicationYear "2018" @default.
• W2891508312 type Work @default.
• W2891508312 sameAs 2891508312 @default.
• W2891508312 citedByCount "5" @default.
• W2891508312 countsByYear W28915083122019 @default.
• W2891508312 countsByYear W28915083122021 @default.
• W2891508312 countsByYear W28915083122022 @default.
• W2891508312 crossrefType "journal-article" @default.
• W2891508312 hasAuthorship W2891508312A5004989711 @default.
• W2891508312 hasAuthorship W2891508312A5011016173 @default.
• W2891508312 hasAuthorship W2891508312A5019650067 @default.
• W2891508312 hasAuthorship W2891508312A5023853605 @default.
• W2891508312 hasAuthorship W2891508312A5030691093 @default.
• W2891508312 hasAuthorship W2891508312A5070052045 @default.
• W2891508312 hasAuthorship W2891508312A5070958796 @default.
• W2891508312 hasAuthorship W2891508312A5091377711 @default.
• W2891508312 hasBestOaLocation W28915083121 @default.
• W2891508312 hasConcept C116263406 @default.
• W2891508312 hasConcept C121608353 @default.
• W2891508312 hasConcept C126322002 @default.
• W2891508312 hasConcept C126838900 @default.
• W2891508312 hasConcept C126894567 @default.
• W2891508312 hasConcept C141071460 @default.
• W2891508312 hasConcept C2775908122 @default.
• W2891508312 hasConcept C2777088508 @default.
• W2891508312 hasConcept C2777416452 @default.
• W2891508312 hasConcept C2778357063 @default.
• W2891508312 hasConcept C2781074409 @default.
• W2891508312 hasConcept C2781413609 @default.
• W2891508312 hasConcept C29730261 @default.
• W2891508312 hasConcept C2989005 @default.
• W2891508312 hasConcept C509974204 @default.
• W2891508312 hasConcept C71924100 @default.
• W2891508312 hasConceptScore W2891508312C116263406 @default.
• W2891508312 hasConceptScore W2891508312C121608353 @default.
• W2891508312 hasConceptScore W2891508312C126322002 @default.
• W2891508312 hasConceptScore W2891508312C126838900 @default.
• W2891508312 hasConceptScore W2891508312C126894567 @default.
• W2891508312 hasConceptScore W2891508312C141071460 @default.
• W2891508312 hasConceptScore W2891508312C2775908122 @default.
• W2891508312 hasConceptScore W2891508312C2777088508 @default.
• W2891508312 hasConceptScore W2891508312C2777416452 @default.
• W2891508312 hasConceptScore W2891508312C2778357063 @default.
• W2891508312 hasConceptScore W2891508312C2781074409 @default.
• W2891508312 hasConceptScore W2891508312C2781413609 @default.
• W2891508312 hasConceptScore W2891508312C29730261 @default.
• W2891508312 hasConceptScore W2891508312C2989005 @default.
• W2891508312 hasConceptScore W2891508312C509974204 @default.
• W2891508312 hasConceptScore W2891508312C71924100 @default.
• W2891508312 hasIssue "1" @default.
• W2891508312 hasLocation W28915083121 @default.
• W2891508312 hasLocation W28915083122 @default.
• W2891508312 hasOpenAccess W2891508312 @default.
• W2891508312 hasPrimaryLocation W28915083121 @default.
• W2891508312 hasRelatedWork W2043597413 @default.
• W2891508312 hasRelatedWork W2055348823 @default.
• W2891508312 hasRelatedWork W2123312949 @default.

• next